Identifying compromise solutions across multiple treatment benefit-harm profiles in multivariate network meta-analysis
Abstract
Health technology assessment often aims to balance evidence across multiple treatments and outcomes and assess treatment benefit-harm profiles. Multivariate network meta-analysis (mvNMA) is well suited to this task, as it synthesizes evidence across treatments and outcomes. However, the potential of mvNMA has been overlooked, leading decision-makers to rely on outcome-specific NMAs that ignore outcome correlations. Based on independent NMA models, previous work proposed methods such as multivariate P-scores or spie charts to assess treatment benefit-harm profiles by yielding across-outcomes treatment hierarchies. In this article, we propose an mvNMA-based framework for assessing treatment benefit-harm profiles. Our framework uses a hybrid-correlation mvNMA model and incorporates DuMouchel priors for treatment effects, enabling estimation of all treatment effects even when outcomes are missing for some treatments. We then extend common NMA ranking metrics, including SUCRA, the probability of being best, and median ranks, to the mvNMA setting. Based on these metrics, we adapt the VIKOR algorithm for mvNMA. This deterministic multicriteria decision method quantifies overall and worst-case treatment performance and, by balancing these aspects, produces an across-outcomes ranking while identifying treatments offering the optimal compromise between these two aspects. To facilitate use of our framework, we developed the R package mvnma. We applied our framework to two clinical datasets: one comparing eleven physical therapy treatments across two outcomes and another comparing nine antidepressants across five outcomes. Our framework provides an alternative strategy for assessing treatment benefit-harm profiles across multiple outcomes and encourages multivariate approaches in applied clinical and policy settings.
Related
- Identifying and disentangling direct and spillover effects using multiple pre-treatment periods
- A Multi‐Task Learning Approach for Identifying Prognostic Variables Across Multiple Historical Clinical Trials
- The promises of multiple experiments: identifying joint distribution of potential outcomes
- A method for generating multivariate multiple orthogonal polynomials
- Factorial Multivariate Bayesian Causal Forests: heterogeneous main and interaction effects of multiple treatments on correlated outcomes
BibTeX
@misc{evrenoglou2026identifying,
title = {{Identifying compromise solutions across multiple treatment benefit-harm profiles in multivariate network meta-analysis}},
author = {Theodoros Evrenoglou and Anna Chaimani and Gerta Rücker and Guido Schwarzer},
howpublished = {arXiv},
year = {2026},
month = oct,
doi = {10.48550/arxiv.2610.04711},
eprint = {2610.04711},
archivePrefix = {arXiv},
url = {https://arxiv.org/abs/2610.04711},
note = {CC BY 4.0},
}
RIS
TY - UNPB
TI - Identifying compromise solutions across multiple treatment benefit-harm profiles in multivariate network meta-analysis
AU - Theodoros Evrenoglou
AU - Anna Chaimani
AU - Gerta Rücker
AU - Guido Schwarzer
PY - 2026
DA - 2026/10/16
PB - arXiv
DO - 10.48550/arxiv.2610.04711
UR - https://arxiv.org/abs/2610.04711
AB - Health technology assessment often aims to balance evidence across multiple treatments and outcomes and assess treatment benefit-harm profiles. Multivariate network meta-analysis (mvNMA) is well suited to this task, as it synthesizes evidence across treatments and outcomes. However, the potential of mvNMA has been overlooked, leading decision-makers to rely on outcome-specific NMAs that ignore outcome correlations. Based on independent NMA models, previous work proposed methods such as multivariate P-scores or spie charts to assess treatment benefit-harm profiles by yielding across-outcomes treatment hierarchies. In this article, we propose an mvNMA-based framework for assessing treatment benefit-harm profiles. Our framework uses a hybrid-correlation mvNMA model and incorporates DuMouchel priors for treatment effects, enabling estimation of all treatment effects even when outcomes are missing for some treatments. We then extend common NMA ranking metrics, including SUCRA, the probability of being best, and median ranks, to the mvNMA setting. Based on these metrics, we adapt the VIKOR algorithm for mvNMA. This deterministic multicriteria decision method quantifies overall and worst-case treatment performance and, by balancing these aspects, produces an across-outcomes ranking while identifying treatments offering the optimal compromise between these two aspects. To facilitate use of our framework, we developed the R package mvnma. We applied our framework to two clinical datasets: one comparing eleven physical therapy treatments across two outcomes and another comparing nine antidepressants across five outcomes. Our framework provides an alternative strategy for assessing treatment benefit-harm profiles across multiple outcomes and encourages multivariate approaches in applied clinical and policy settings.
ER -